Oxygen-Ozone Therapy: A Critical Evaluation
This book represents the first serious attempt to explain the fundamental basis of ozonetherapy and is a relevant step towards achieving further progress. Ozone is now considered a real drug and, after reacting with body fluids, releases messengers and activates several mechanisms which are able to elicit multiple biological effects. The therapeutic window has been defined and, contrary to the dogma that `ozone is toxic any way you deal with it', it has been shown that ozone toxicity can be tamed and even totally avoided. New powerful methodologies have been devised and astonishing clinical results in vascular and infectious diseases have already been achieved. An exciting novelty is the induction of an adaptive response that implies the unsuspected possibility of arresting cell degeneration due to endogenous chronic oxidative stress. However, further basic and controlled clinical studies need to be performed to fully exploit ozone's therapeutic potentials and to establish the real validity of this therapy. Authoritative scientists and clinicians should abandon their prejudice and consider the profound difference between endogenous oxidative stress and the new concept of ozonetherapeutic `shock'. If this happens, we could soon have a simple and inexpensive tool to restore health in millions of patients. This book has been written in a plain scientific language and can be read by scientists and clinicians, as well as by patients keen on regaining a state of well being.
What people are saying - Write a review
Other editions - View all
acid activity antioxidant antioxidant system approach ARMD ascorbate ascorbic acid bilirubin biochemical Biol biological Bocci BOEX cancer cells chronic clinical compounds Crohn's disease cytokines damage disease drugs EBOO effects of ozone endothelial enhance enzymes erythrocytes evaluate experimental exposed exposure Figure free radical growth factor haemolysis heparin hepatitis hormones human immune improvement increase induce infection infusion inhibit insufflation ischaemia ischaemic leukocytes levels LOPs lymphocytes medicine membrane metabolic ml of blood molecules Moreover NF-KB normal O3 concentration Os-AHT oxidative stress oxygen oxygen-ozone ozone concentration ozone dose ozonetherapy ozonized blood ozonized oil ozonized water patients performed pg/ml physicians physiological placebo effect plasma platelets possible problem production proteins reaction reactive rectal insufflation redox reduced reinfusion release remains reported response risk saline samples side effects synthesis TBARS therapeutic therapy tissue toxic treated treatment tumour ulcers vascular venous viral vitamin vivo volume
Page 411 - O'Reilly, MS; Holmgren, L.; Shing, Y.; Chen, C.; Rosenthal, RA; Moses, M.; Lane, WS; Cao, Y.; Sage, EH and Folkman, J. (1994) Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma.
Page 400 - Jackson KA, Majka SM, Wang H, Pocius J, Hartley CJ, Majesky MW, Entman ML, Michael LH, Hirschi KK, Goodell MA. Regeneration of ischemic cardiac muscle and vascular endothelium by adult stem cells.
Page 401 - Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent.
Page 421 - A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease.
Page 393 - Elliott MJ, Maini RN, Feldmann M, Kalden JR, Antoni C, Smolen JS, Leeb B. Breedveld FC, Macfarlane JD, Bijl H, et al. Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis.
Page 381 - Alkhatib, G., Combadiere, C., Broder, CC, Feng, Y., Kennedy, PE, Murphy, PM, and Berger, EA (1996) CC CKR5: a RANTES, MIP-1 alpha, MIP-1 beta receptor as a fusion cofactor for macrophage-tropic HIV-1.
Page 416 - A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. N. Engl. J. Med., 316, 889, 1987.